{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:51:14Z","timestamp":1761094274322,"version":"build-2065373602"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T00:00:00Z","timestamp":1349136000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:p>Major depressive disorder (<jats:styled-content style=\"fixed-case\">MDD<\/jats:styled-content>) affects 121 million people globally and is one of the leading causes of functional disability worldwide. As a recurrent disorder, <jats:styled-content style=\"fixed-case\">MDD<\/jats:styled-content> is associated with significant morbidity and functional disability as well as high direct and indirect costs to the health care system. Although several drug therapies are available for treating <jats:styled-content style=\"fixed-case\">MDD<\/jats:styled-content>, many patients do not achieve a sustained remission. Vilazodone was approved by the United States Food and Drug Administration in 2011 and has a distinctive pharmacology profile, as the drug is a selective serotonin reuptake inhibitor and serotonin 5\u2010<jats:styled-content style=\"fixed-case\">HT<\/jats:styled-content><jats:sub>1A<\/jats:sub> receptor partial agonist. In two 8\u2010week, double\u2010blind, placebo\u2010controlled trials, vilazodone's overall rate of response was similar to other antidepressants for the treatment of <jats:styled-content style=\"fixed-case\">MDD<\/jats:styled-content>. Compared with placebo, remission rates were not significantly different in one trial and were not reported in the second trial. Vilazodone was generally well tolerated, with nausea and diarrhea being the most frequent adverse events reported. Postmarketing studies and further active comparative studies will provide additional insight to the potential benefits and safety of this novel drug.<\/jats:p>","DOI":"10.1002\/j.1875-9114.2012.01121","type":"journal-article","created":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T09:50:00Z","timestamp":1349171400000},"page":"958-965","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Vilazodone for the Treatment of Major Depressive Disorder"],"prefix":"10.1002","volume":"32","author":[{"given":"Maryam","family":"Iranikhah","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice Samford University McWhorter School of Pharmacy Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri M.","family":"Wensel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Samford University McWhorter School of Pharmacy Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela R.","family":"Thomason","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Samford University McWhorter School of Pharmacy Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-90"},{"key":"e_1_2_10_3_1","unstructured":"WHO resources page.World Health Organization web site. Available fromhttp:\/\/www.WHO.int\/mental_health\/management\/depression\/definition\/en\/index.html. Accessed August 15 2011."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.07.002"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.23.3095"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199201000-00007"},{"key":"e_1_2_10_7_1","first-page":"45","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000"},{"volume-title":"Practice guideline for the treatment of patients with major depressive disorder","author":"The American Psychiatric Association","key":"e_1_2_10_8_1"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.06.041"},{"volume-title":"Viibryd (vilazodone) packet insert","year":"2011","author":"Forest Laboratories, Inc","key":"e_1_2_10_10_1"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903286396"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2008.00067.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm040793q"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.01.018"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.034280"},{"volume-title":"Drug approval package. Viibryd (vilazodone hydrochloride) Tablets","author":"U.S. Food and Drug Administration","key":"e_1_2_10_16_1"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11r06984"},{"key":"e_1_2_10_18_1","first-page":"84","article-title":"Vilazodone for major depressive disorder","volume":"10","author":"Kalia R","year":"2011","journal-title":"Curr Psychiatr"},{"volume-title":"Avandia (rosiglitazone) packet insert","year":"2011","author":"GlaxoSmithKline","key":"e_1_2_10_19_1"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.01.110"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10m06596"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04637"},{"key":"e_1_2_10_23_1","unstructured":"Advisory Committees. Food and Drug Administration Web site. Available fromhttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4273b1_04-descriptionofmadrshamddepressionr%281%29.pdf. Accessed August 15 2011."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31822c6741"},{"key":"e_1_2_10_25_1","unstructured":"ClinicalTrials.gov.Safety efficacy and tolerability of vilazodone in major depressive disorder (VLZ\u2010MD\u201003). Available fromhttp:\/\/www.clinicaltrials.gov\/ct2\/NCT01473394?term=vilazodone&rank=2. Accessed February 6 2012."},{"key":"e_1_2_10_26_1","unstructured":"ClinicalTrials.gov.Safety and efficacy of vilazodone in major depressive disorder (VLZ\u2010MD\u201001). Available fromhttp:\/\/www.clinicaltrials.gov\/ct2\/NCT01473381?term=vilazodone&rank=1. Accessed February 6 2012."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.2012.01121","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.2012.01121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:55:48Z","timestamp":1761062148000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.2012.01121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1002\/j.1875-9114.2012.01121"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.2012.01121","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"2012-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}